// App-Quantinova.ai

2574 : A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.

Researchers

Presenter

  • Jordan Berlin

Principal Investigators

  • Ramesh K. Ramanathan

  • John H. Strickler

  • Matthew W. Dudley

  • Vincent L. Giranda

  • Yoon-Koo Kang

  • Tae-You Kim

  • Stacie Peacock Shepherd

  • Hao Xiong

  • Robert Hetman

  • Caroline Nickner

Medical Centers

  • Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Duke University Medical Center, Durham, NCTGen - Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZVanderbilt-Ingram Cancer Center, Nashville, TN

  • AbbVie, Inc., North Chicago, IL

  • AbbVie, Inc., Saint-Laurent, QC, Canada

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • L-leucovorin

  • Veliparib

  • FOLFIRI

  • Adrucil injection

Outcome

  • Positive

Study Design

  • drug-drug interaction

Phase

  • I

Study Id's

  • NCT01123876

Sponsors

  • Abbvie

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved